NRXSNYSEElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Neuraxis, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$7.85+0.15 (+1.95%)
Close on Oct 19, 2026
- Market cap
- $95.14M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$4.82 (+159.1%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Neuraxis, INC grew revenue 65.2% to $5.32M over the twelve months to Jun 30, 2026. Free cash flow was -$6.46M.
Revenue
$5.32M
+65.2% vs. a year earlier
Operating income
-$7.68M
TTM Q2 2026
Free cash flow
-$6.46M
FY2025
EPS, diluted
-$0.79
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $95.14M
- P/E ratio
- –
- Price to sales
- 17.90
- Price to book
- 14.13
- Dividend yield
- –
- Free cash flow yield
- -6.79%
Fundamentals
- Revenue
- $5.32M
- Net income
- -$7.68M
- EPS, diluted
- -$0.79
- Free cash flow
- -$6.46M
- Book value per share
- $0.56
- Diluted shares
- 12M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
$5.32M+65.2% YoY
Gross profit
$4.55M+66.6% YoY
Operating income
-$7.68M
Net income
-$7.68M
EPS, diluted
-$0.79
Free cash flow
–
Reported periodTrailing twelve months